Nivolumab Plus Folfox Therapy Shows Promising Results in Gastric Cancer Patient with Hemodialysis

A 65-year-old man with diabetic nephropathy and recurrent gastric cancer with liver metastases has undergone a unique treatment regimen involving nivolumab plus modified FOLFOX6 therapy, with encouraging results despite the patient's challenging medical condition. According to a case report published in Internal Medicine, the patient's cancer was initially treated with standard chemotherapy, but the patient developed ascites and elevated CA125 levels, rendering the standard treatment ineffective. The researchers from Akita University decided to modify the treatment plan by reducing the dose of oxaliplatin and discontinuing the bolus administration of 5-fluorouracil, while continuing to administer nivolumab.

Key Takeaways:

• The patient's cancer was initially treated with standard chemotherapy, but the treatment was ineffective due to the patient's poor general condition and elevated CA125 levels.
• The researchers modified the treatment plan by reducing the dose of oxaliplatin and discontinuing the bolus administration of 5-fluorouracil, while continuing to administer nivolumab.
• The modified treatment plan was successful in achieving a significant reduction in the patient's symptoms and improving their general condition.
• The researchers emphasized the importance of dose modification and discontinuation depending on the patient's general condition and blood test results during the treatment course.
• The case report highlights the challenges of treating patients with complex medical conditions and the need for personalized treatment plans.
• The researchers involved in the study include Taichi Yoshida, Naoaki Kodama, Tomohiro Matsumoto, Daiki Taguchi, Kazuhiro Shimazu, Koji Fukuda, and Hiroyuki Shibata from Akita University.

Statistics:

• The patient was 65 years old and had diabetic nephropathy and recurrent gastric cancer with liver metastases at the time of treatment.
• The patient received reduced doses of oxaliplatin and 5-fluorouracil, while continuing to administer nivolumab.
• The patient's CA125 levels decreased significantly after the modified treatment plan was initiated.
• The study highlights the importance of dose modification and discontinuation in patients with complex medical conditions.

Sources:

• NewsRx. Investigators at Akita University Describe Findings in Gastric Cancer (Administration of Nivolumab Plus Folfox Therapy To a Patient With Gastric Cancer Undergoing Hemodialysis: a Case Report). Immunotherapy Weekly. October 15, 2025; p 2003.
• Internal Medicine. Administration of Nivolumab Plus Folfox Therapy To a Patient With Gastric Cancer Undergoing Hemodialysis: a Case Report. 2025.